BioSpace News Archive

Biovica, active in cancer diagnostics, announces that the company will establish its own US CLIA lab for the launch of DiviTum®TKa on the US market.

Kairos Pharma, Ltd., a privately held clinical stage biotechnology company focused on drug resistance and immunotherapy for cancer, announced that its activated T cell therapy, KROS 201, has received FDA approval to proceed with a Phase 1 clinical trial in patients with recurrent glioblastoma, a type of brain cancer.

I Peace, Inc., a Palo Alto-based biotech start-up, announced that the company had tripled its capacity to manufacture GMP grade iPS cells and iPSC-derived differentiated cells by expanding its facility.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the full-year ended December 31, 2021 and recent business achievements.

Akoya Biosciences, Inc., The Spatial Biology Company®, announced its financial results for the fourth quarter and full year ending December 31, 2021.

Emergent BioSolutions Inc. announced that members of the company’s executive management team will participate in the following investor conferences.

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, reported financial results for the quarter and full year ended December 31, 2021.

Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, reported the grant of an aggregate of 18,900 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 48,900 shares of Arcutis’ common stock to four newly hired employees.

STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that John Bagdasarian has joined the company as Vice President of Professional Relations.

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced fourth quarter and full year 2021 results and provided a corporate update.